» Articles » PMID: 6235074

Paradoxical Presence of T Cell Anergy During Successful T Cell-dependent Tumour Immunotherapy: Characterization of a State of T Cell 'amnaesia' Following Systemic Administration of C. Parvum

Overview
Date 1984 Jul 1
PMID 6235074
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic administration of Corynebacterium parvum causes T cell-dependent regression of an established methylcholanthrene-induced murine fibrosarcoma beginning 10 days after Cp injection. At this time, tumour specific effector T cell responses measured by reactivity in a T helper cell assay or in a Winn assay disappear only to return later. We refer to this temporary lapse in T cell reactivity as immunological 'amnaesia'. Antigen specific T cell responses within all lymphoid organs appear to be affected. The 'amnaesic' state is characterised by the presence of primed T cells but the absence of T effector cells and suppressor cells. The differentiation of the primed T cells is blocked probably as a result on the non-delivery of a differentiation signal. There are several possible mechanisms which could account for this; the one we prefer is that cells are prevented from entering T cell-dependent cell interaction areas within lymphoid organs. This state of T cell 'amnaesia' may underlie anergy in some inflammatory, infectious and neoplastic diseases. The apparent paradox of T cell-dependent tumour regression occurring in mice with depressed T cell responses is discussed.

Citing Articles

Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy.

Nesseler J, Lee M, Nguyen C, Kalbasi A, Sayre J, Romero T Cancers (Basel). 2020; 12(3).

PMID: 32197352 PMC: 7140082. DOI: 10.3390/cancers12030714.


A Century of Radiation Therapy and Adaptive Immunity.

Schaue D Front Immunol. 2017; 8:431.

PMID: 28443099 PMC: 5387081. DOI: 10.3389/fimmu.2017.00431.


Incidence and growth of methylcholanthrene-induced tumors in mice with altered immunological status.

Golubic M, Matovic M, Marusic M Cancer Immunol Immunother. 1986; 23(2):130-6.

PMID: 3490910 PMC: 11038127. DOI: 10.1007/BF00199819.


Induction of tolerance to a murine fibrosarcoma in two zones of dosage--the involvement of suppressor cells.

McBride W, Howie S Br J Cancer. 1986; 53(6):707-11.

PMID: 2941045 PMC: 2001406. DOI: 10.1038/bjc.1986.122.

References
1.
Woodruff M, Dunbar N, Ghaffar A . The growth of tumours in T-cell deprived mice and their response to treatment with Corynebacterium parvum. Proc R Soc Lond B Biol Sci. 1973; 184(1074):97-102. DOI: 10.1098/rspb.1973.0034. View

2.
Moore K, McBride W . Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy. Br J Cancer. 1983; 47(6):797-802. PMC: 2011359. DOI: 10.1038/bjc.1983.133. View

3.
Toujas L, Dazord L, Martin A, Guelfi J . Simultaneous stimulation of plaque forming cells and depression of cellular immunity to sheep erythrocytes, after adjuvant treatment. Biomedicine. 1973; 19(11):503-5. View

4.
Milas L, Hunter N, Basic I, Withers H . Complete regressions of an established murine fibrosarcoma induced by systemic application of Corynebacterium granulosum. Cancer Res. 1974; 34(10):2470-5. View

5.
Scott M . Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection. J Natl Cancer Inst. 1974; 53(3):855-60. DOI: 10.1093/jnci/53.3.855. View